Rexahn Pharma (RNN) Receives USPTO Notice of Allowance for Patent Related to RX-3117
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall St opens lower as Meta Platforms, economic data weigh
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Dollar firmer on higher U.S. inflation; yen sinks vs euro, US currency
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Rexahn Pharmaceuticals Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Patent Covering the Manufacturing of RX-3117 – A Cancer Cell Specific Anticancer Agent
October 31, 2016 9:00 AM EDTROCKVILLE, Md., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent for claims related to the synthesis of its novel anti-cancer investigational drug candidate, RX-3117. RX-3117 is currently in stage 2 of a Phase Ib/IIa clinical trial in patients with metastatic pancreatic cancer.
"Rexahn is pleased to expand the intellectual property protection for... More
